Form 4: Alignment Healthcare President Sells Shares

Alignment Healthcare's President, Dawn C. Maroney, reported sales of common stock totaling 328,152 shares under a pre-arranged 10b5-1 plan.

Summary

• Dawn Christine Maroney, President of Alignment Healthcare, Inc. (ALHC), reported sales of common stock.
• A total of 100,000 shares were sold on January 2, 2026, at a weighted-average price of $20.0345 per share, with prices ranging from $19.45 to $20.37.
• An additional 228,152 shares were sold on January 6, 2026, at a weighted-average price of $21.3349 per share, with prices ranging from $20.91 to $21.62.
• These transactions were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan adopted on May 22, 2025.
• Following the transaction on January 2, 2026, Maroney beneficially owned 1,285,167 shares of common stock.
• Following the transaction on January 6, 2026, Maroney beneficially owned 1,057,015 shares of common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, the explicit mention of a Rule 10b5-1 plan mitigates concerns about the timing of the sales, suggesting a pre-planned personal financial management strategy rather than a reaction to new company-specific information.

Positives

• The reported sales were executed under a pre-arranged Rule 10b5-1 plan, indicating a structured approach to managing personal equity rather than a reaction to immediate market conditions or non-public information.

Negatives

• The transactions represent a reduction in the direct beneficial ownership of common stock by a key executive, which can sometimes be perceived as a neutral to slightly negative signal by investors.

Future Outlook

This Form 4 filing reports past and scheduled future insider transactions and does not contain specific forward-looking statements or guidance regarding the company's operational or financial performance.

Management Comments

• The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the reported ranges.

Industry Context

This insider transaction report is specific to Alignment Healthcare, Inc. and does not provide broader industry trends or competitive analysis. It reflects an individual executive's equity management rather than a strategic industry move.

Stakeholder Impact

• Shareholders: The reduction in direct beneficial ownership by a key executive could be noted by shareholders, though the pre-planned nature under Rule 10b5-1 lessens the potential for negative interpretation regarding company prospects.

Key Dates

Recommendation

The filing reports pre-planned insider sales under a Rule 10b5-1 plan, which is a routine event for executives managing their personal portfolios. While insider selling can sometimes be a negative signal, the pre-arranged nature mitigates concerns about immediate market timing. This transaction alone does not provide sufficient information to alter a fundamental investment thesis, thus a 'hold' recommendation is appropriate for existing investors to monitor further developments.

Keywords

Alignment Healthcare, ALHC, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Executive Compensation, Dawn Maroney